Concord Biotech consolidated profit rises 43.7% in Q1FY26

Concord Biotech Limited reported a significant improvement in profitability for the first quarter of FY26, with consolidated net profit rising 43.7% year-on-year to ₹5769.69 lakh. The Ahmedabad-based biotechnology firm posted consolidated revenue from operations of ₹25748.90 lakh for the quarter ended June 30, 2026, marking a 26.2% increase over the ₹20398.76 lakh recorded in Q1FY25. This performance underscores strong operational momentum as the company navigates its growth trajectory.

The unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on July 31, 2026. The filing was submitted to the stock exchanges pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Chairman and Managing Director Sudhir Vaid signed off on the results, which were also published in newspapers on August 01, 2026.

Financial Highlights

The company’s standalone results mirrored the consolidated strength, with net profit after tax reaching ₹6119.37 lakh, compared to ₹4256.55 lakh in the same period last year. Standalone total income from operations stood at ₹26051.71 lakh, up from ₹20398.76 lakh in Q1FY25. The basic earnings per share (EPS) on a standalone basis rose to ₹5.85 from ₹4.07 in the corresponding quarter of the previous year.

Particulars	Standalone Q1FY26	Standalone Q1FY25	Consolidated Q1FY26	Consolidated Q1FY25
Total Income from Operations (₹ lakh)	26,051.71	20,398.76	25,748.90	20,398.76
Net Profit After Tax (₹ lakh)	6,119.37	4,256.55	5,769.69	4,405.78
Basic EPS (₹)	5.85	4.07	5.52	4.21
Diluted EPS (₹)	5.85	4.07	5.52	4.21

On a consolidated basis, the net profit before tax was ₹7834.31 lakh, an increase from ₹5873.18 lakh in Q1FY25. The total comprehensive income for the period was reported at ₹7475.83 lakh, compared to ₹4123.90 lakh in the prior year quarter. Equity share capital remained unchanged at ₹1046.16 lakh across both standalone and consolidated statements.

What the Numbers Show

The divergence between standalone and consolidated net profit margins suggests efficient management of subsidiary-level costs or inter-company eliminations. While standalone revenue exceeded consolidated revenue by approximately ₹302.81 lakh, the standalone net profit was higher than the consolidated figure by ₹349.68 lakh. This pattern indicates that the parent entity is currently driving the majority of the group's profitability, with subsidiaries potentially contributing more to top-line volume than bottom-line retention in this quarter.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.44%	+13.30%	+10.50%	+24.14%	-19.96%	+50.04%

Concord Biotech Limited delivered robust financial results for the first quarter of FY27, reporting a consolidated net profit (PAT) of ₹57.7 crore, a 31% increase from ₹44.1 crore in Q1FY26. The growth was underpinned by a 26% rise in revenue from operations to ₹257.5 crore, reflecting broad-based demand across its Active Pharmaceutical Ingredients (API) and formulation segments. This performance signals strengthening market share and operational efficiency for the biopharma firm.

The company filed its unaudited standalone and consolidated financial results with the National Stock Exchange of India Limited and BSE Limited on August 01, 2026, pursuant to Regulation 30 and Schedule III Part A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was signed by Paritosh Trivedi, Company Secretary and Compliance Officer.

Financial Performance Breakdown

Revenue growth was primarily driven by the API segment, which saw a 42% year-on-year increase to ₹218.9 crore from ₹153.8 crore in Q1FY26. In contrast, formulation revenue declined 23% to ₹38.6 crore from ₹50.2 crore. Geographically, export revenue surged 46% to ₹121.7 crore, significantly outpacing domestic revenue growth of 12% to ₹135.8 crore.

Metric	Q1FY27	Q1FY26	YoY Change
Revenue from Operations (₹ Cr)	257.5	204.0	+26%
EBITDA (₹ Cr)	82.4	61.4	+34%
PAT (₹ Cr)	57.7	44.1	+31%
Gross Profit Margin (%)	78.9%	77.9%	+100 bps
EBITDA Margin (%)	32.0%	30.1%	+190 bps
PAT Margin (%)	22.4%	21.6%	+80 bps

Excluding the impact of the injectable facility and expenses related to Stellon Biotech, EBITDA margins stood at 37% for Q1FY27. Cost of goods sold increased to ₹54 crore from ₹45 crore, while employee costs rose to ₹44 crore from ₹38 crore.

Operational Highlights

Ankur Vaid, Joint Managing Director & Chief Executive Officer, attributed the performance to increased wallet share among existing customers and the addition of new products. The company noted advanced discussions with large customers and a robust pipeline targeting 2-3 product launches annually. Regulatory milestones included USFDA approvals for Abbreviated New Drug Applications (ANDAs) for Mycophenolate Mofetil and Tofacitinib Tablets.

The company also completed inspections by ANVISA at its Limbasi facility and by the Pharmacy and Poisons Board (PPB) of Kenya and the National Drug Authority (NDA) of Uganda at its Unit-II formulation facility. Additionally, Concord Biotech received a Silver Medal from EcoVadis, placing it among the top 15% of companies assessed globally for sustainability.

What the Numbers Show

The divergence between API and formulation revenue highlights a strategic shift or temporary headwind in the latter segment. While API revenue surged 42%, formulation revenue contracted 23%. However, the overall margin expansion—EBITDA margins up 190 basis points—suggests that the higher-margin API mix is driving profitability despite the volume drop in formulations. The 46% export growth further indicates successful penetration into regulated international markets, reducing reliance on domestic demand.